Ursodeoxycholic Acid Market to Surpass US$ 1,075.5 Million by 2026 - Coherent Market Insights

Global Ursodeoxycholic Acid Market, by Dosage Form (Solid Dosage Form and Liquid Dosage Form), by Mode of Extraction (Synthetic and Biological), by Application (Gallstones, Cystic Fibrosis, Liver Cirrhosis, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 457.3 million in 2017 and is projected to exhibit a CAGR of 10.1% over the forecast period (2018 – 2026).

Development of liquid ursodeoxycholic acid can offer growth opportunities to market players, since UDCA is currently prescribed only in solid form. Introducing a liquid formulation of ursodeoxycholic acid would provide healthcare professionals an alternate dosing method for patients who have difficulty swallowing tablets or capsules. Major players in the market are focusing on receiving patents for liquid formulation of UDCA. For instance, in June 2016, Retrophin, Inc. signed a definitive agreement to purchase rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC. Furthermore, in 2017, Retrophin announced plans to file a new drug application (NDA) with the U.S. Food and Drug Administration for the liquid formulation of ursodeoxycholic acid, to be used for treating primary biliary cholangitis (PBC).

Browse 32 Market Data Tables and 22 Figures spread through 160 Pages and in-depth TOC on ‘Ursodeoxycholic Acid Market’- Global Forecast to 2026, by Dosage Form (Solid Dosage Form and Liquid Dosage Form), by Mode of Extraction (Synthetic and Biological), by Application (Gallstones, Cystic Fibrosis, Liver Cirrhosis and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Ursodeoxycholic Acid Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/ursodeoxycholic-acid-market-2199

The Asia Pacific region is expected to be dominant in the ursodeoxycholic acid market over the forecast period, due to reasons such as high prevalence of diseases such as gallstones and liver cirrhosis. For instance, according to the data published by the OMICS International, in India, liver cirrhosis resulted in 1.2 million deaths in 2013, increasing from 0.8 million deaths in 1990. Furthermore, key players in the region are focusing on gaining approval for development of ursodeoxycholic acid for novel indication. For instance, In February, 2019, EA Pharma is developing nor-ursodeoxycholic acid for treatment of primary sclerosing cholangitis (PSC), and non-alcoholic steatohepatitis (NASH) in Japan.

Key Takeaways of the Ursodeoxycholic Acid Market:

• The global ursodeoxycholic acid market is expected to exhibit a CAGR of 10.1% over the forecast period, owing to rapid research in development of novel ursodeoxycholic acid. High prevalence of diseases such as gallstone and liver cirrhosis is expected to fuel growth of the market.
• Among dosage form, solid dosage form segment held dominant position in the ursodeoxycholic acid market in 2018, owing to development of capsule and tablet form of Ursodeoxycholic acid (UDCA) by various manufacturers such as Grindex and Intercept Pharmaceuticals, for treatment of primary biliary cholangitis.
• Among application, gall stones segment held dominant position in the ursodeoxycholic acid market in 2018, owing to increasing incidence of the condition. For instance, according to the American Gastroenterological Association 2017 report, gallstones is affecting 10-15% of the U.S. population annually, which accounts for around 25 million people.
• Companies operating in the global ursodeoxycholic acid market include Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.